Monopar Says $129.4 Million Can Fund Its Drug Push Through At Least March 2028

The funding estimate includes a potential Wilson disease drug launch as Monopar works to finish its FDA application.

Share
Monopar Says $129.4 Million Can Fund Its Drug Push Through At Least March 2028

Monopar Therapeutics, which is developing a once-daily pill for Wilson disease, expects its $129.4 million in cash, cash equivalents and investments to fund operations through at least March 31, 2028. The company said in Thursday's SEC filing that the estimate includes a potential commercial launch of ALXN1840, alongside regulatory work and cancer-drug development.

Cash For An Approval Push

Monopar held those funds as of September 30. Its spending plan also covers internal research and continued work on the MNPR-101 cancer programs.

The company expects to finish its application for FDA approval of ALXN1840 within the next several weeks, according to its earnings release. It began the submission on July 22, 2026, under an FDA-authorized process that lets reviewers receive finished sections while the company prepares the rest.

Monopar appointed Jeffrey D. Kent as executive vice president and head of medical affairs on August 19, 2026. Kent leads that organization as the company prepares for possible approval.

The funding horizon remains management's estimate. Monopar warned that changes in its operating plans, development and commercialization costs, or contractual milestone payments could shorten it.

Higher Costs Widen The Loss

Monopar's third-quarter net loss widened to $6.2 million, or $0.72 per share, from $3.4 million, or $0.48 per share, a year earlier.

Research and development expenses rose to $4.4 million from $2.6 million. Monopar attributed the increase mainly to contractor, consulting and personnel costs. Lower ALXN1840 manufacturing spending partly offset those increases.

Administrative expenses reached $3 million, versus $1.5 million a year earlier. The company said personnel costs, including stock-based pay, and contractor and consulting expenses were the principal reasons.

Interest income rose to $1.3 million from $0.7 million. Monopar attributed that increase to earnings on Treasury securities and commercial paper, plus higher bank balances supported by approximately $91.9 million in net proceeds from its September 2025 capital raise.

Persistent Disease Behind The Drug Bet

Wilson disease prevents the body from properly clearing copper, allowing toxic accumulation in the liver, brain and other organs. Monopar licenses ALXN1840 exclusively worldwide from Alexion; its medicines remain in testing.

Earlier November presentations described the disease burden patients carried into the drug's late-stage trial. Only 47% of previously treated patients met recommended copper targets. Among patients on standard treatment for more than 12 months, 31% had urinary copper levels above the recommended range.

Cirrhosis affected 39% of previously treated patients and 30% of untreated patients. Neurologic symptoms affected 79% and 83%, respectively; psychiatric symptoms affected 75% and 70%. Among evaluable patients, 73% had at least two of those manifestations.

Frederick K. Askari, an associate professor of internal medicine at the University of Michigan Health System, described the baseline disease burden in both patient groups as striking.

Monopar said ALXN1840 met the late-stage trial's main goal, producing greater sustained copper mobilization than standard treatment over 48 weeks. A separate November presentation reported no molybdenum toxicity and normal serum uric acid during six years of treatment.

Beyond Wilson disease, Monopar is developing MNPR-101-Zr for cancer imaging and MNPR-101-Lu for treatment in early-stage trials enrolling patients in Australia. MNPR-101-Ac remains a late preclinical treatment candidate.

Completing the ALXN1840 application is Monopar's next stated milestone. Its cash plan includes a launch, but FDA approval remains pending.

Sources

More on Monopar Therapeutics

All Monopar Therapeutics (MNPR) coverage →